{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:39:20Z","timestamp":1789389560348,"version":"build-2803163510"},"reference-count":71,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Over the past several generations, primary hyperparathyroidism (PHTP) has undergone a change in its clinical presentation in many countries from a symptomatic disease to an asymptomatic one. The reasons for this change in clinical presentation are related to the widespread use of biochemical screening tests, to the measurement of PTH more routinely in the evaluation of metabolic bone disease and to the status of vitamin D sufficiency in the population. Along with recognition of a broader clinical spectrum of disease, including a more recently recognized normocalcemic variant, has come an appreciation that the evaluation of classic target organs that can be affected in PHPT, such as the skeleton and the kidneys, require more advanced imaging technology for complete evaluation. It is clear that even in asymptomatic patients, evidence for microstructural disease in the skeleton and calcifications in the kidneys can be demonstrated often. Potential non-classical manifestations of PHPT related to neurocognition and the cardiovascular system continue to be of interest. As a result of these advances, revised guidelines for the management of asymptomatic PHPT have been recently published to help the clinician determine whether surgery is appropriate or whether a more conservative approach is acceptable.<\/ns4:p>","DOI":"10.12688\/f1000research.7039.1","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T05:55:04Z","timestamp":1451886904000},"page":"1","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Primary Hyperparathyroidism"],"prefix":"10.12688","volume":"5","author":[{"given":"Leonardo","family":"Bandeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2016,1,4]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"406-24","DOI":"10.1590\/S0004-27302013000600002","article-title":"Diagnosis and management of primary hyperparathyroidism--a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism.","volume":"57","author":"F Bandeira","year":"2013","journal-title":"Arq Bras Endocrinol Metabol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1276-1287","DOI":"10.1001\/jama.1934.02750160010003","article-title":"Hyperparathyroidism: A common and polymorphic condition as illustrated by seventeen proved cases from one clinic.","volume":"102","author":"F Albright","year":"1934","journal-title":"J Am Med Assoc."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"33-9","DOI":"10.1016\/j.jocd.2012.12.001","article-title":"Normocalcemic primary hyperparathyroidism.","volume":"16","author":"N Cusano","year":"2013","journal-title":"J Clin Densitom."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"3983-7","DOI":"10.1210\/jc.2013-4491","article-title":"Primary hyperparathyroidism in young people. When should we perform genetic testing for multiple endocrine neoplasia 1 (MEN-1)?","volume":"99","author":"T Lassen","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"142-4","DOI":"10.1016\/j.ando.2015.03.027","article-title":"Genetic evaluation in primary hyperparathyroidism: What investigation? For which patients?","volume":"76","author":"L Groussin","year":"2015","journal-title":"Ann Endocrinol (Paris)."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"397-402","DOI":"10.1007\/s10354-013-0235-z","article-title":"Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy.","volume":"163","author":"R Gasser","year":"2013","journal-title":"Wien Med Wochenschr."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"69-74","DOI":"10.4137\/CMED.S13147","article-title":"Epidemiology of Primary Hyperparathyroidism and its Non-classical Manifestations in the City of Recife, Brazil.","volume":"6","author":"C Eufrazino","year":"2013","journal-title":"Clin Med Insights Endocrinol Diabetes."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"519-26","DOI":"10.1590\/S0100-879X2007000400010","article-title":"Analysis of the diagnostic presentation profile, parathyroidectomy indication and bone mineral density follow-up of Brazilian patients with primary hyperparathyroidism.","volume":"40","author":"U Oliveira","year":"2007","journal-title":"Braz J Med Biol Res."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"2990-3011","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).","volume":"97","author":"R Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1404-10","DOI":"10.1359\/jbmr.090304","article-title":"Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity.","volume":"24","author":"C Eller-Vainicher","year":"2009","journal-title":"J Bone Miner Res."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"485-93","DOI":"10.1111\/j.1365-2265.2008.03520.x","article-title":"Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK.","volume":"71","author":"N Yu","year":"2009","journal-title":"Clin Endocrinol (Oxf)."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"13-17","DOI":"10.4158\/EP10308.RA","article-title":"Benign familial hypocalciuric hypercalcemia.","volume":"17","author":"J Varghese","year":"2011","journal-title":"Endocr Pract."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"3570-9","DOI":"10.1210\/jc.2014-1414","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.","volume":"99","author":"R Eastell","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"3580-94","DOI":"10.1210\/jc.2014-1415","article-title":"Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.","volume":"99","author":"S Silverberg","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"309-315","DOI":"10.1016\/B978-0-12-397166-1.00020-5","article-title":"Clinical Presentation of Primary Hyperparathyroidism: A Global Perspective","author":"F Bandeira","year":"2015"},{"key":"ref-16","first-page":"158-65","article-title":"Primary hyperparathyroidism in women: a tale of two cities--New York and Beijing.","volume":"45","author":"J Bilezikian","year":"2000","journal-title":"Int J Fertil Womens Med."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"162-9","DOI":"10.4248\/BR201302005","article-title":"Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai.","volume":"1","author":"J Liu","year":"2013","journal-title":"Bone Res."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"553-61","DOI":"10.1590\/0004-2730000003381","article-title":"Bone disease in primary hyperparathyroidism.","volume":"58","author":"F Bandeira","year":"2014","journal-title":"Arq Bras Endocrinol Metabol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"14-21","DOI":"10.1016\/j.jocd.2012.11.005","article-title":"Asymptomatic primary hyperparathyroidism.","volume":"16","author":"S Silverberg","year":"2013","journal-title":"J Clin Densitom."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1196-203","DOI":"10.1056\/NEJM199204303261806","article-title":"Management of acute hypercalcemia.","volume":"326","author":"J Bilezikian","year":"1992","journal-title":"N Engl J Med."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"317-330","DOI":"10.1016\/B978-0-12-397166-1.00021-7","article-title":"Asymptomatic Primary Hyperparathyroidism","author":"S Silverberg","year":"2015"},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11926-015-0523-2","article-title":"Hyperparathyroidism and Bone Health.","volume":"17","author":"F Bandeira","year":"2015","journal-title":"Curr Rheumatol Rep."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"2306-12","DOI":"10.1210\/jc.2008-2006","article-title":"Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism.","volume":"94","author":"E Vignali","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1309-15","DOI":"10.1210\/jc.2014-3708","article-title":"Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology.","volume":"100","author":"C Cipriani","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"147-55","DOI":"10.1007\/s11914-013-0142-7","article-title":"Clinical imaging of bone microarchitecture with HR-pQCT.","volume":"11","author":"K Nishiyama","year":"2013","journal-title":"Curr Osteoporos Rep."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1029-40","DOI":"10.1002\/jbmr.1841","article-title":"Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women.","volume":"28","author":"E Stein","year":"2013","journal-title":"J Bone Miner Res."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1941-7","DOI":"10.1002\/jbmr.98","article-title":"Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: A case-control study using HR-pQCT.","volume":"25","author":"S Hansen","year":"2010","journal-title":"J Bone Miner Res."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"493-503","DOI":"10.1590\/0004-2730000003456","article-title":"Trabecular bone score: perspectives of an imaging technology coming of age.","volume":"58","author":"B Silva","year":"2014","journal-title":"Arq Bras Endocrinol Metabol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"518-30","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: a noninvasive analytical method based upon the DXA image.","volume":"29","author":"B Silva","year":"2014","journal-title":"J Bone Miner Res."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"554-61","DOI":"10.1016\/j.jocd.2013.07.001","article-title":"Trabecular bone score is associated with volumetric bone density and microarchitecture as assessed by central QCT and HRpQCT in Chinese American and white women.","volume":"16","author":"B Silva","year":"2013","journal-title":"J Clin Densitom."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1963-70","DOI":"10.1210\/jc.2012-4255","article-title":"Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism.","volume":"98","author":"B Silva","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"1137-42","DOI":"10.4158\/EP14074.OR","article-title":"Silent renal stones in primary hyperparathyroidism: prevalence and clinical features.","volume":"20","author":"S Cassibba","year":"2014","journal-title":"Endocr Pract."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"908-11","DOI":"10.2214\/AJR.07.3160","article-title":"Primary hyperparathyroidism: is there an increased prevalence of renal stone disease?","volume":"191","author":"J Suh","year":"2008","journal-title":"AJR Am J Roentgenol."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"40-7","DOI":"10.1016\/j.jocd.2012.11.008","article-title":"Nontraditional manifestations of primary hyperparathyroidism.","volume":"16","author":"M Walker","year":"2013","journal-title":"J Clin Densitom."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"331-339","DOI":"10.1016\/B978-0-12-397166-1.00022-9","article-title":"Normocalcemic PHPT","author":"N Cusano","year":"2015"},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"3001-5","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.","volume":"92","author":"H Lowe","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-37","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/128352","article-title":"Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone?","volume":"2012","author":"L Amaral","year":"2012","journal-title":"J Osteoporos."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1748-53","DOI":"10.1210\/jc.2005-2102","article-title":"Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women.","volume":"91","author":"I Charopoulos","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"764-6","DOI":"10.1007\/s12020-012-9694-z","article-title":"Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women.","volume":"42","author":"A Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"Endocrine."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"277-84","DOI":"10.1111\/cen.12819","article-title":"Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden.","volume":"83","author":"G Kontogeorgos","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"172-8","DOI":"10.1530\/EC-15-0030","article-title":"Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy.","volume":"4","author":"E Vignali","year":"2015","journal-title":"Endocr Connect."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"2734-41","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.","volume":"98","author":"N Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"153-9","DOI":"10.1016\/j.surg.2006.12.004","article-title":"Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up).","volume":"141","author":"C Caillard","year":"2007","journal-title":"Surgery."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"139-43","DOI":"10.1590\/S0004-27302013000200007","article-title":"Lower quality of life in longstanding mild primary hyperparathyroidism.","volume":"57","author":"A Veras","year":"2013","journal-title":"Arq Bras Endocrinol Metabol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"753-60","DOI":"10.1530\/EJE-11-0301","article-title":"Patients with surgically cured primary hyperparathyroidism have a reduced quality of life compared with population-based healthy sex-, age-, and season-matched controls.","volume":"165","author":"A Amstrup","year":"2011","journal-title":"Eur J Endocrinol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"5415-22","DOI":"10.1210\/jc.2004-0028","article-title":"Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism.","volume":"89","author":"D Rao","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"1951-8","DOI":"10.1210\/jc.2008-2574","article-title":"Neuropsychological features in primary hyperparathyroidism: a prospective study.","volume":"94","author":"M Walker","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"3561-9","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.","volume":"99","author":"J Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"335-9","DOI":"10.1210\/jc.2008-1763","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.","volume":"94","author":"J Bilezikian","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"N2-11","DOI":"10.1210\/jc.2002-021370","article-title":"Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.","volume":"17","author":"J Bilezikian","year":"2002","journal-title":"J Bone Miner Res."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"3595-606","DOI":"10.1210\/jc.2014-2000","article-title":"The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.","volume":"99","author":"R Udelsman","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"534-9","DOI":"10.1016\/j.surg.2014.11.010","article-title":"The utility of 4-dimensional computed tomography for preoperative localization of primary hyperparathyroidism in patients not localized by sestamibi or ultrasonography.","volume":"157","author":"K Day","year":"2015","journal-title":"Surgery."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"1286-94","DOI":"10.1016\/j.surg.2011.09.016","article-title":"Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism.","volume":"150","author":"T Wang","year":"2011","journal-title":"Surgery."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"843-9","DOI":"10.1007\/s00423-009-0510-z","article-title":"Evaluation of Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally invasive parathyroidectomy.","volume":"394","author":"M Barczynski","year":"2009","journal-title":"Langenbecks Arch Surg."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"280-5","DOI":"10.1001\/archsurg.2011.5","article-title":"An optimal algorithm for intraoperative parathyroid hormone monitoring.","volume":"146","author":"M Richards","year":"2011","journal-title":"Arch Surg."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"1150-8","DOI":"10.1002\/jbmr.1540","article-title":"Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography.","volume":"27","author":"S Hansen","year":"2012","journal-title":"J Bone Miner Res."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"151-8","DOI":"10.1007\/s00774-013-0473-6","article-title":"Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism.","volume":"32","author":"S Tournis","year":"2014","journal-title":"J Bone Miner Metab."},{"key":"ref-58","first-page":"640-4","article-title":"The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy.","volume":"35","author":"S Alonso","year":"2012","journal-title":"J Endocrinol Invest."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"523-8","DOI":"10.1308\/003588413X13629960048712","article-title":"Recurrent urolithiasis following parathyroidectomy for primary hyperparathyroidism.","volume":"95","author":"C Rowlands","year":"2013","journal-title":"Ann R Coll Surg Engl."},{"key":"ref-60","first-page":"887-90","article-title":"[Clinical analysis of primary hyperparathyroidism with kidney stones: 23 cases report].","volume":"51","author":"Z Zha","year":"2013","journal-title":"Zhonghua Wai Ke Za Zhi."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"3069-73","DOI":"10.1210\/jc.2015-2132","article-title":"Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism.","volume":"100","author":"F Tassone","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"542-8","DOI":"10.1007\/s00268-013-2285-1","article-title":"Improvement of sleep disturbance and insomnia following parathyroidectomy for primary hyperparathyroidism.","volume":"38","author":"S Murray","year":"2014","journal-title":"World J Surg."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"305-10","DOI":"10.1007\/s12020-009-9211-1","article-title":"Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency.","volume":"36","author":"M Isidro","year":"2009","journal-title":"Endocrine."},{"key":"ref-64","first-page":"871-5","article-title":"[Alendronate increases bone mineral density in patients with symptomatic primary hyperparathyroidism].","volume":"56","author":"W Misiorowski","year":"2005","journal-title":"Endokrynol Pol."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"3319-25","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.","volume":"89","author":"A Khan","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"1295-302","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.","volume":"26","author":"R Cesareo","year":"2015","journal-title":"Osteoporos Int."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"527-35","DOI":"10.1530\/EJE-14-0877","article-title":"Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.","volume":"172","author":"A Khan","year":"2015","journal-title":"Eur J Endocrinol."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"1466-71","DOI":"10.1245\/s10434-011-2065-9","article-title":"Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.","volume":"19","author":"J Norman","year":"2012","journal-title":"Ann Surg Oncol."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"E9-18","DOI":"10.1210\/jc.2010-1221","article-title":"Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.","volume":"96","author":"M Peacock","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"283-7","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.","volume":"39","author":"A Faggiano","year":"2011","journal-title":"Endocrine."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"3607-18","DOI":"10.1210\/jc.2014-1417","article-title":"Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism.","volume":"99","author":"C Marcocci","year":"2014","journal-title":"J Clin Endocrinol Metab."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-1\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-1\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-1\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T09:42:41Z","timestamp":1553247761000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-1\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,4]]},"references-count":71,"URL":"https:\/\/doi.org\/10.12688\/f1000research.7039.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.7577.r11702","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.7577.r11701","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.7577.r11702","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.7577.r11701","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,4]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-1\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.7577.r11702, Robert Wermers, Department of Medicine, Division of Endocrinology, Mayo Clinic, Rochester, MN, USA, 04 Jan 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1\/v1#referee-response-11702","order":0,"name":"referee-response-11702","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.7577.r11701, Frederick Singer, John Wayne Cancer Institute, Providence Saint Johns Health Center, Santa Monica, CA, USA, 04 Jan 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1\/v1#referee-response-11701","order":1,"name":"referee-response-11701","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}